Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B.

IF 3.9 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Research Pub Date : 2024-05-28 DOI:10.1111/hepr.14076

Yuji Ikeda, Ayato Murata, Hiroki Nago, Masahiro Yamaguchi, Rihwa Om, Yuichro Terai, Yuji Kita, Sho Sato, Shunsuke Sato, Yuji Shimada, Takuya Genda

{"title":"Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B.","authors":"Yuji Ikeda, Ayato Murata, Hiroki Nago, Masahiro Yamaguchi, Rihwa Om, Yuichro Terai, Yuji Kita, Sho Sato, Shunsuke Sato, Yuji Shimada, Takuya Genda","doi":"10.1111/hepr.14076","DOIUrl":null,"url":null,"abstract":"Aim: Measurement of O-glycosylated middle hepatitis B surface antigen (HBsAg glycan isomer, HBsAgGi) has been developed to quantify hepatitis B virus (HBV) infectious virions and distinguish them from subviral particles. This study aimed to evaluate the association between serum HBsAg seroclearance and serum HBV virions measured by HBsAgGi in patients with chronic hepatitis B (CHB).Methods: Serum HBsAgGi levels were quantified in 232 treatment-naïve patients with CHB genotype C. Cox proportional hazards analysis was used to calculate hazard ratios (HRs) for factors associated with HBsAg seroclearance.Results: Baseline HBsAgGi levels showed significant differences among HBV phenotypes. During a median follow-up period of 7.4 years, 22 of the 232 patients achieved HBsAg seroclearance. Multivariate analysis demonstrated that quantitative HBsAg, nucleoside/nucleotide analog therapy during the follow-up period, and HBsAgGi levels were independent predictors of seroclearance. The adjusted HR indicated that the HBsAg seroclearance probability in patients with low HBsAgGi (≤3.5log ng/mL) was over five times higher than that in patients with high HBsAgGi. Kaplan-Meier analysis indicated that the 10-year probabilities of HBsAg seroclearance were 21.0% and 3.0% in patients with low and high HBsAgGi levels, respectively (p < 0.001), and that patients with high HBsAgGi levels showed low seroclearance probabilities irrespective of the other predictors.Conclusion: Serum HBV infectious virion levels, measured using HBsAgGi, may be a novel predictor of HBsAg seroclearance.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hepr.14076","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Measurement of O-glycosylated middle hepatitis B surface antigen (HBsAg glycan isomer, HBsAgGi) has been developed to quantify hepatitis B virus (HBV) infectious virions and distinguish them from subviral particles. This study aimed to evaluate the association between serum HBsAg seroclearance and serum HBV virions measured by HBsAgGi in patients with chronic hepatitis B (CHB).

Methods: Serum HBsAgGi levels were quantified in 232 treatment-naïve patients with CHB genotype C. Cox proportional hazards analysis was used to calculate hazard ratios (HRs) for factors associated with HBsAg seroclearance.

Results: Baseline HBsAgGi levels showed significant differences among HBV phenotypes. During a median follow-up period of 7.4 years, 22 of the 232 patients achieved HBsAg seroclearance. Multivariate analysis demonstrated that quantitative HBsAg, nucleoside/nucleotide analog therapy during the follow-up period, and HBsAgGi levels were independent predictors of seroclearance. The adjusted HR indicated that the HBsAg seroclearance probability in patients with low HBsAgGi (≤3.5log ng/mL) was over five times higher than that in patients with high HBsAgGi. Kaplan-Meier analysis indicated that the 10-year probabilities of HBsAg seroclearance were 21.0% and 3.0% in patients with low and high HBsAgGi levels, respectively (p < 0.001), and that patients with high HBsAgGi levels showed low seroclearance probabilities irrespective of the other predictors.

Conclusion: Serum HBV infectious virion levels, measured using HBsAgGi, may be a novel predictor of HBsAg seroclearance.

查看原文本刊更多论文

乙型肝炎表面抗原（HBsAg）聚糖异构体可预测慢性乙型肝炎患者的 HBsAg 血清清除率。

目的：O-糖基化中间乙型肝炎表面抗原（HBsAg聚糖异构体，HBsAgGi）的测定已被开发用于量化乙型肝炎病毒（HBV）感染性病毒并将其与亚病毒颗粒区分开来。本研究旨在评估慢性乙型肝炎（CHB）患者血清 HBsAg 血清清除率与通过 HBsAgGi 测定的血清 HBV 病毒之间的关联：对232名基因型为C型的未经治疗的慢性乙型肝炎（CHB）患者的血清HBsAgGi水平进行了定量分析，并采用Cox比例危险分析法计算与HBsAg血清清除率相关因素的危险比（HRs）：结果：基线 HBsAgGi 水平在 HBV 表型之间存在显著差异。在中位 7.4 年的随访期间，232 名患者中有 22 人实现了 HBsAg 血清清除。多变量分析表明，HBsAg定量、随访期间的核苷/核苷酸类似物治疗以及HBsAgGi水平是血清清除的独立预测因素。调整后的 HR 表明，低 HBsAgGi（≤3.5log ng/mL）患者的 HBsAg 血清清除概率是高 HBsAgGi 患者的 5 倍多。Kaplan-Meier 分析表明，HBsAgGi 水平低的患者和 HBsAgGi 水平高的患者 10 年后 HBsAg 血清清除的概率分别为 21.0% 和 3.0% （P使用 HBsAgGi 测量血清 HBV 感染性病毒水平可能是预测 HBsAg 血清清除率的一种新方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology Research 医学-胃肠肝病学

CiteScore

8.30

自引率

14.30%

发文量

124

审稿时长

1 months

期刊介绍： Hepatology Research (formerly International Hepatology Communications) is the official journal of the Japan Society of Hepatology, and publishes original articles, reviews and short comunications dealing with hepatology. Reviews or mini-reviews are especially welcomed from those areas within hepatology undergoing rapid changes. Short communications should contain concise definitive information.

文献相关原料

公司名称	产品信息	采购帮参考价格